
ALXO Stock Forecast & Price Target
ALXO Analyst Ratings
Bulls say
ALX Oncology Holdings Inc. is making significant strides in the clinical-stage immuno-oncology sector with its innovative pipeline featuring the CD47 blocker, evorpacept, which is currently undergoing phase 1 and 2 trials. The company's expansion into new products, such as the EGFR-targeting ADC ALX2004, indicates a commitment to enhancing treatment safety and efficacy, particularly through improved linker-payload stability. Promising early trial results, including a median progression-free survival (mPFS) of approximately 9.5 months for patients treated with evorpacept in combination with other therapies, underscore a potentially positive trajectory for both ALX's product candidates and its overall market position.
Bears say
ALX Oncology Holdings Inc. has revised its financial model, indicating diminished confidence in its gastric cancer program and awaiting crucial proof of concept data for additional tumor types. The company lowered its peak market penetration rate estimate for Head and Neck cancer due to increased competition, reflecting a more cautious outlook on its revenue potential. Furthermore, the absence of any reported revenues in the fourth quarter of 2024, alongside a significant net loss per share, coupled with high risks associated with FDA approval pathways, contribute to the prevailing negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ALXO Analyst Forecast & Price Prediction
Start investing in ALXO
Order type
Buy in
Order amount
Est. shares
0 shares